Sign up to save your podcasts
Or
Share Weight Loss and CV Outcomes with Ozempic, Munjaro and Similar Drugs with Dr. Peter Toth
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Weight Loss and CV Outcomes with Ozempic, Munjaro and Similar Drugs with Dr. Peter Toth
Let us know your thoughts. We would love to hear from you.
Dr Peter Toth discusses with Dr. Thomas Nero the new classes of diabetes medications, SGLT2 inhibitors (eg Jardiance) and GLP1 receptor agonists (eg Ozempic and Munjaro.) These drugs have been in the news due to an impressive effect on weight reduction, but they also improve cardiovascular outcomes in diabetic and non-diabetic patients.
View all episodes
By Thomas Nero, MDLet us know your thoughts. We would love to hear from you.
Dr Peter Toth discusses with Dr. Thomas Nero the new classes of diabetes medications, SGLT2 inhibitors (eg Jardiance) and GLP1 receptor agonists (eg Ozempic and Munjaro.) These drugs have been in the news due to an impressive effect on weight reduction, but they also improve cardiovascular outcomes in diabetic and non-diabetic patients.